Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.

Abstract

This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tumor was found to be a KRAS wild-type and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib. It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically.

• Authors: Bach Ardalan, Jose Ignacio Azqueta, Jonathan England, Tiffany Alyssa Eatz
• Journal: Cold Spring Harbor molecular case studies (Cold Spring Harb Mol Case Stud) Vol. 7 Issue 5 (10 2021) ISSN: 2373-2873 [Electronic] United States
• PMID: 34667063 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2021 Ardalan et al.; Published by Cold Spring Harbor Laboratory Press.

Chemical References

• KRAS protein, human
• BRAF protein, human
• Proto-Oncogene Proteins B-raf
• Mitogen-Activated Protein Kinase Kinases
• Proto-Oncogene Proteins p21(ras)

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Pancreatic Ductal (drug therapy, genetics)
• Female
• Humans
• Mitogen-Activated Protein Kinase Kinases
• Pancreatic Neoplasms (drug therapy, genetics)
• Proto-Oncogene Proteins B-raf (genetics)
• Proto-Oncogene Proteins p21(ras) (genetics)